Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 187Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 66Neoplasms 62Ovarian Neoplasms 59Glioblastoma 40Carcinoma, Hepatocellular 36Neoplasm Metastasis 32Colonic Neoplasms 27Carcinoma, Renal Cell 24Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 21Rectal Neoplasms 17Pancreatic Neoplasms 17Lung Neoplasms 17Stomach Neoplasms 15Liver Neoplasms 15Brain Neoplasms 14Non-Squamous Non-Small Cell Lung Cancer 13Endometrial Neoplasms 11Recurrence 10Glioma 10Carcinoma, Ovarian Epithelial 10Triple Negative Breast Neoplasms 9Melanoma 9Gastrointestinal Neoplasms 9Advanced Solid Tumors 9Solid Cancers 7Peritoneal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

motexafin gadolinium 1Talaporfin 1Rhenium 1Poly I-C 1Mitomycin 1Lomustine 1Folfox protocol 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Recurrence, Local × Bevacizumab × Clear all
NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡